UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

Selective RET kinase inhibition for patients with RET-altered cancers

Annals of oncology, 2018-08, Vol.29 (8), p.1869-1876

2018

Link zum Volltext

Verfügbarkeit prüfen

Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1

Gene therapy, 2006-02, Vol.13 (3), p.225-234

2006

Link zum Volltext

Verfügbarkeit prüfen

391 LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancers

European journal of cancer (1990), 2014-11, Vol.50, p.125-125

2014

Link zum Volltext

Verfügbarkeit prüfen

The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S145

2016

Link zum Volltext

Verfügbarkeit prüfen

The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S144

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Tissue Distribution of a Ribozyme Directed Against Hepatitis C Virus RNA Following Subcutaneous or Intravenous Administration in Mice

Hepatology (Baltimore, Md.), 2000-09, Vol.32 (3), p.640-646

2000

Link zum Volltext

Verfügbarkeit prüfen

Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors

Clinical cancer research, 2000-05, Vol.6 (5), p.2094-2103

2000

Link zum Volltext

Verfügbarkeit prüfen

Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations

European journal of cancer (1990), 2022-10, Vol.174, p.S81-S81

2022

Link zum Volltext

Verfügbarkeit prüfen

In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations

European journal of cancer (1990), 2022-10, Vol.174, p.S81-S81

2022

Link zum Volltext

Verfügbarkeit prüfen

Vectorial secretion of extracellular matrix proteins, matrix-degrading proteinases, and tissue inhibitor of metalloproteinases by endothelial cells

The Journal of biological chemistry, 1990-01, Vol.265 (1), p.445-451

1990

Link zum Volltext

Verfügbarkeit prüfen

162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations

European journal of cancer supplements, 2010, Vol.8 (7), p.56-56

2010

Link zum Volltext

Verfügbarkeit prüfen

441 - The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S144

2016

Link zum Volltext

Verfügbarkeit prüfen

442 - The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S145

2016

Link zum Volltext

Verfügbarkeit prüfen

Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers

Bone (New York, N.Y.), 2011-02, Vol.48 (2), p.389-398

2011

Link zum Volltext

Verfügbarkeit prüfen

Ribozymes as Tools for Therapeutic Target Validation in Arthritis

The Journal of immunology (1950), 2000-07, Vol.165 (1), p.493-498

2000

Link zum Volltext

Verfügbarkeit prüfen

In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.5104-5104

2009

Link zum Volltext

Verfügbarkeit prüfen

Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens

Current issues in molecular biology, 2000-10, Vol.2 (4), p.113

2000

Link zum Volltext

Verfügbarkeit prüfen

Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells

Cancer research (Chicago, Ill.), 1990-04, Vol.50 (8), p.2322-2329

1990

Link zum Volltext

Verfügbarkeit prüfen

Wound healing in the fetus. Possible role for inflammatory macrophages and transforming growth factor-beta isoforms

Wound repair and regeneration, 1994-03, Vol.2 (2), p.104-112

1994

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse

Antisense & nucleic acid drug development, 1999-06, Vol.9 (3), p.271-277

1999

Link zum Volltext

Verfügbarkeit prüfen

Expression of metalloproteinases and metalloproteinases inhibitors by fetal astrocytes and glioma cells

Cancer research (Chicago, Ill.), 1990, Vol.50 (8), p.2322-2329

1990

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1440: Identification of a novel EGFR sparing brain penetrant ErbB2 inhibitor with activity against oncogenic ErbB2 mutations

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1440-1440

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective RET kinase inhibition for patients with RET-altered cancers

Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1

391 LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancers

The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

Pharmacokinetics and Tissue Distribution of a Ribozyme Directed Against Hepatitis C Virus RNA Following Subcutaneous or Intravenous Administration in Mice

Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors

Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations

In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations

Vectorial secretion of extracellular matrix proteins, matrix-degrading proteinases, and tissue inhibitor of metalloproteinases by endothelial cells

162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations

441 - The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

442 - The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers

Ribozymes as Tools for Therapeutic Target Validation in Arthritis

In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab

Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens

Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells

Wound healing in the fetus. Possible role for inflammatory macrophages and transforming growth factor-beta isoforms

Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse

Expression of metalloproteinases and metalloproteinases inhibitors by fetal astrocytes and glioma cells

Abstract 1440: Identification of a novel EGFR sparing brain penetrant ErbB2 inhibitor with activity against oncogenic ErbB2 mutations

Suchergebnisse filtern